Welcome to our dedicated page for Iteos Therapeutics news (Ticker: ITOS), a resource for investors and traders seeking the latest updates and insights on Iteos Therapeutics stock.
iTeos Therapeutics, Inc. (ITOS) is a clinical-stage biopharmaceutical company that has focused on immuno-oncology, developing therapies designed to counteract immunosuppressive pathways in the tumor microenvironment. Company communications describe programs targeting the TIGIT/CD226 axis, the adenosine pathway, ENT1, TREM2, and PTPN1/2, with candidates such as belrestotug, EOS-984, EOS-215, and inupadenant.
The news flow around iTeos has included clinical trial updates, collaboration decisions, strategic reviews, and corporate transactions. For example, the company has reported interim data from Phase 2 and Phase 3 studies in first-line non-small cell lung cancer and head and neck squamous cell carcinoma, including the GALAXIES Lung-201, GALAXIES Lung-301, GALAXIES H&N-202, and TIG-006 trials. In May 2025, iTeos and its partner GSK decided to terminate the belrestotug development program after interim analyses did not meet predefined criteria for progression-free survival and response rate improvements compared with monotherapy.
News items have also covered early-stage pipeline progress, such as Phase 1 development of EOS-984, IND-enabling and early clinical work for EOS-215, and preclinical data on a PTPN1/2 inhibitor. The company has presented data at major scientific and medical meetings, including the American Association for Cancer Research Annual Meeting and the ESMO Immuno-Oncology Congress, highlighting translational and preclinical findings on its candidates and pathway signatures.
In 2025, iTeos announced a strategic shift, stating its intention to wind down operations and focus on maximizing shareholder value through its cash position and potential asset sales. Subsequent news detailed an agreement for iTeos to be acquired by Concentra Biosciences through a tender offer and merger, followed by delisting from Nasdaq and deregistration of its common stock. This news page provides a record of these developments, allowing investors, researchers, and other readers to review the company’s clinical, scientific, and corporate milestones over time.
iTeos Therapeutics (ITOS) has initiated patient enrollment for two Phase 2 trials focusing on advanced cancer treatments. The trials evaluate the efficacy of EOS-448, an anti-TIGIT monoclonal antibody, in combination with GSK’s Jemperli for head and neck squamous cell carcinoma, and inupadenant, an adenosine A2A receptor antagonist, with chemotherapy for non-small cell lung cancer. As of June 30, 2022, the company reported a cash balance of $792 million, sufficient to support operations through 2026. Recent R&D expenses have risen to $26.9 million, reflecting increased clinical activities.
iTeos Therapeutics, Inc. (Nasdaq: ITOS) announced that its CEO, Michel Detheux, will participate in a panel discussion at the 2022 Wedbush PacGrow Healthcare Conference on August 9, 2022, at 8:00 a.m. ET. The topic will focus on opportunities and challenges in immuno-oncology.
A live webcast can be accessed on the company's website, with an archived replay available for 30 days post-event. iTeos is developing innovative immuno-oncology therapeutics, including the anti-TIGIT antibody EOS-448 and the adenosine A2A receptor antagonist inupadenant, aimed at enhancing the immune response against cancer.
Domain Therapeutics has appointed Dr. Xavier Leroy as Chief Scientific Officer (CSO), enhancing its leadership in immuno-oncology and GPCR programs. Previously serving as Chief Technology Officer, Dr. Leroy will now oversee research and the transition of the company to a clinical-stage biopharmaceutical entity. He highlights the opportunity to develop first-in-class candidates targeting new GPCRs. Dr. Leroy's extensive experience includes senior roles at Actelion Pharmaceuticals and significant contributions to raising $75M in funding for immuno-oncology projects.
iTeos Therapeutics (NASDAQ: ITOS) reported strong financial results for Q1 2022, achieving a net income of $69.6 million, or $1.96 per basic share. The company's cash reserves rose to $824 million, providing funding into 2026 for ongoing clinical trials. Key developments include the enrollment of patients in pivotal trials for EOS-448, an anti-TIGIT monoclonal antibody, and inupadenant, an A2A receptor antagonist. Enhanced evidence of target engagement in tumors was presented at the AACR 2022, fueling optimism for their innovative cancer therapies.
iTeos Therapeutics has announced promising data on its anti-TIGIT antibody, EOS-448, presented at the AACR Annual Meeting 2022. The study revealed a decrease in TIGIT-positive cells in tumor biopsies, marking a significant treatment effect. Preclinical and clinical data demonstrate EOS-448's ability to reduce suppressive immune cell populations, indicating effective engagement of FcγR. These findings support ongoing clinical trials aimed at developing EOS-448 as a potent immuno-oncology therapy for patients with advanced cancers.
iTeos Therapeutics (ITOS) has made significant strides in its immuno-oncology pipeline, reporting a cash position of $848.5 million as of December 31, 2021, ensuring funding through 2026. The company is advancing its clinical trials for EOS-448, an anti-TIGIT antibody, and inupadenant, an A2A receptor antagonist, in collaboration with GSK. Key initiatives include multiple registration-directed trials and triplet regimen studies, signaling robust clinical development plans. In 2021, iTeos reported a net income of $214.5 million, an improvement from a net loss the previous year.
iTeos Therapeutics, a clinical-stage biopharmaceutical company, announced that CEO Michel Detheux will present at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 12:50 p.m. ET. The presentation will focus on the company's innovative immuno-oncology therapies. A live webcast will be available on their website, with an archived replay accessible for 30 days. iTeos is advancing multiple clinical-stage programs, including EOS-448, an anti-TIGIT antibody in collaboration with GSK, and inupadenant, an adenosine A2A receptor antagonist.
iTeos Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Michel Detheux, will participate in two investor conferences on February 17, 2022. The 11th Annual SVB Leerink Global Healthcare Conference at 12:00 p.m. ET and Citi’s 2022 Virtual Immuno-Oncology Summit at 1:30 p.m. ET are the events scheduled for the same day. The company focuses on developing advanced immuno-oncology therapeutics, including its leading product candidates EOS-448 and inupadenant. A live webcast will be hosted on its website, with recordings available for 30 days.
iTeos Therapeutics (Nasdaq: ITOS) announced its clinical development plan for EOS-448, an anti-TIGIT monoclonal antibody, and inupadenant, an A2A receptor antagonist. The company is progressing with 11 clinical studies, including three planned registration-directed trials. EOS-448 is being investigated in combination therapies with anti-PD-1 agents, while inupadenant is evaluated with chemotherapy and pembrolizumab. Yvonne McGrath has been promoted to chief scientific officer, crucial for advancing iTeos’s immunotherapy pipeline targeting difficult-to-treat cancers.
iTeos Therapeutics, a clinical-stage biopharmaceutical company, announced that CEO Michel Detheux will present at the 40th Annual J.P. Morgan Conference on January 11, 2022, at 11:15 a.m. ET. The presentation will focus on the company's advancements in immuno-oncology therapeutics. A live webcast will be accessible on the company's investor website, with a replay available for 30 days post-event. iTeos is developing innovative therapies, including the anti-TIGIT antibody EOS-448 and the adenosine A2A receptor antagonist inupadenant, aimed at enhancing anti-cancer responses.
FAQ
What is the current stock price of Iteos Therapeutics (ITOS)?
What is the market cap of Iteos Therapeutics (ITOS)?
